Scott A Gangloff's most recent trade in Akero Therapeutics Inc was a trade of 2,600 Common Stock done at an average price of $19.6 . Disclosure was reported to the exchange on Aug. 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Akero Therapeutics Inc | Scott A. Gangloff | Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.62 per share. | 15 Aug 2025 | 2,600 | 26,351 (0%) | 0% | 19.6 | 51,012 | Common Stock |
| Akero Therapeutics Inc | Scott A. Gangloff | Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 2,600 | 17,784 | - | - | Stock option (Right to Buy) | |
| Akero Therapeutics Inc | Scott A. Gangloff | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 23.87 per share. | 30 Jun 2025 | 299 | 23,751 (0%) | 0% | 23.9 | 7,137 | Common Stock |
| Akero Therapeutics Inc | Scott A. Gangloff | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 54.84 per share. | 18 Jun 2025 | 848 | 23,452 (0%) | 0% | 54.8 | 46,504 | Common Stock |